Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide During LVAD Implantation
NCT00060840Phase 2Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Jul 2003
- Primary completion
- Jun 2008
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of nitric oxide in heart failure (HF) (2 arms), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: The Number of Subjects With Left Ventricular Failure During Left Ventricular Assistance Device (LVAD) Placement After Cardio Pulmonary Bypass, as Determined by Failure Criteria, After Administration… at 28 days. Started Jul 2003; status: completed.
02
Drugs
nitric oxide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT00060840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00060840.